Startups
Innovative cancer research studies developed through industry partnerships and networks. Supporting ECOG-ACRIN Cancer Research Group's efforts to advance cancer care
Overview
Location
United States, Pennsylvania, Philadelphia
Employees
11-50
Phone
+1 215-789-7001
Mentions in press and media 10
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Aug 6, 2021 | Oncolytics Biotech® Reports 2021 Second Quarter Development Highlights and Financial Results | |
| Aug 6, 2021 | Oncolytics Biotech : reg; Reports 2021 Second Quarter Development Highlights and Financial Results | - Clinical AWARE-1 trial achieves primary endpoint and confirms that pelareorep is an immunotherapeutic agent which synergizes with checkpoint inhibitors: Validation of clinical development strategy in breast cancer - Phase 2 BRACELET-1 (br... |
| Jul 5, 2021 | Oncolytics Biotech : reg; Reports 2021 First Quarter Development Highlights and Financial Results | - AWARE-1 clinical data validate clinical development strategy by confirming pelareorep's anti-tumor mechanism of action known to be associated with improved patient outcomes and ability to synergize with checkpoint inhibitors - Preclinical... |
| May 7, 2021 | ONCOLYTICS BIOTECH INC. Oncolytics Biotech : reg; Reports 2021 First Quarter Development Highlights and Financial Results | - AWARE-1 clinical data validate clinical development strategy by confirming pelareorep's anti-tumor mechanism of action known to be associated with improved patient outcomes and ability to synergize with checkpoint inhibitors - Preclinical... |
| May 7, 2021 | Oncolytics Biotech® Reports 2021 First Quarter Development Highlights and Financial Results | - AWARE-1 clinical data validate clinical development strategy by confirming pelareorep's anti-tumor mechanism of action known to be associated with improved patient outcomes and ability to synergize with checkpoint inhibitors - Preclinical... |
| May 7, 2021 | Oncolytics Biotech® Reports 2021 First Quarter Development Highlights and Financial Results | |
| Mar 5, 2021 | Oncolytics Biotech® Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights | |
| Mar 5, 2021 | Oncolytics Biotech® Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights | - New clinical data highlight pelareorep's potential to boost the effectiveness of checkpoint inhibitors - Clinical demonstration of pelareorep reversing immunosuppressive tumor microenvironments - On track to report clinical biomarker and ... |
| Aug 5, 2020 | Oncolytics Biotech® Reports 2020 Second Quarter Financial Results and Operational Highlights | SAN DIEGO and CALGARY, Alberta, Aug. 4, 2020 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced its financial results and operational highlights for the quarter ended June 30, 2020. All dollar amounts are expressed ... |
Reviews 0
FAQ about PrECOG Cancer Research Group
What has the press written about PrECOG Cancer Research Group?
Parsers VC has collected 10 articles mentioning PrECOG Cancer Research Group, among them “Oncolytics Biotech® Reports 2021 Second Quarter Development Highlights and Financial Results” (Aug 6, 2021) and “Oncolytics Biotech : reg; Reports 2021 Second Quarter Development Highlights and Financial Results” (Aug 6, 2021).
Is PrECOG Cancer Research Group still active?
Yes, PrECOG Cancer Research Group is active; its latest activity on Parsers VC dates from Aug 6, 2021.